Research Article

In vitro therapy investigation for breast cancer by B13-chloroquine application

Volume: 17 Number: 2 August 15, 2024
TR EN

In vitro therapy investigation for breast cancer by B13-chloroquine application

Abstract

Cancer disease still remains to be strong treat for public health. New treatment approaches and agents with low side effects are needed for the treatment of breast cancer. Based on these, herein was aimed to investigate the cytotoxicity of a combination comprising a ceramidase inhibitor (B13) and an autophagy inhibitor (chloroquine) on human breast cancer cell line. The antiproliferative activity was tested by Sulforhodamine B and ATP viability assays. For ultrastructural and morphological changes and apoptotic signs of MCF-7 cells were used TEM and confocal microscopy techniques. Results showed the high cytotoxic and antiproliferative activities of the combination along with the ultrastructural and morphological changes indicating apoptosis. B13+Chloroquine combinations found to be effective on inducing cell death on MCF-7 cells and antiproliferative and cytotoxic effects on cells. Consequently, the new combination is suggested as good candidate for further investigations to be an anti-cancer agent.

Keywords

Supporting Institution

Anadolu University

Project Number

This study was supported by Anadolu University Scientific Research Project Unit with project number: 1901S002.

Thanks

This study was supported by Anadolu University Scientific Research Project Unit with project number: 1901S002.

References

  1. References
  2. [1] Mughal, T. A., Aslam, F., Yousaf, Z., Numrah, N., & Ping, C. L. (2020). In vitro cytotoxic activity of Zaleya pentandra L. extracts against the breast cancer adenocarcinoma cell line MCF-7. Journal of Pakistan Medical Association, 70, 35-41.
  3. [2] Shen, S., Huang, L. S, Xiao, X. L., Zhu, X. F., Xiong, D. D., Cao, X. M., Wei, K. L., Chen, G., & Feng, Z. B. (2017). miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. Oncology Reports, 38, 368-376.
  4. [3] Nedaei, S. H., Akbari, H., & Yaghoubi, H. (2019). Cytotoxicity effects of green synthesized silver nanoparticles by using the extract of Tuber spp. on breast cancer (MCF-7) cells. Journal of Babol University Medical Sciences, 21, 242-48.
  5. [4] Jardim, D. L., De Melo Gagliato, D., Nikanjam, M., Barkauskas, D. A., & Kurzrock, R. (2020). Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology, 9, 1710052.
  6. [5] Verbaanderd, C., Maes, H., Schaaf, M.B., Sukhatme, V. P., Pantziarka, P., Sukhatme, V., Agostinis, P., & Bouche, G. (2017). Repurposing drugs in oncology (redo)-chloroquine and hydroxychloroquine as anti-cancer agents. E. Cancer Medical Science. 23 (11) 781.
  7. [6] Manic, G., Obrist, F., Kroemer, G., Vitale, I., & Galluzzi, L., (2014). Chloroquine and hydroxychloroquine for cancer therapy. Molecular and Cellular Oncology, 15, e29911.
  8. [7] Al-Bari, M.A. (2015). Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. Journal of Antimicrobial Chemotherapy, 70(6), 1608-1621.

Details

Primary Language

English

Subjects

Cell Development, Proliferation and Death

Journal Section

Research Article

Early Pub Date

May 11, 2024

Publication Date

August 15, 2024

Submission Date

August 31, 2023

Acceptance Date

March 6, 2024

Published in Issue

Year 2024 Volume: 17 Number: 2

APA
Çömlekçi, E., Vejselova Sezer, C., Kutlu, H. M., Yaylacı, Ö. K., & Kus, G. (2024). In vitro therapy investigation for breast cancer by B13-chloroquine application. Biological Diversity and Conservation, 17(2), 105-111. https://doi.org/10.46309/biodicon.2024.1353221
AMA
1.Çömlekçi E, Vejselova Sezer C, Kutlu HM, Yaylacı ÖK, Kus G. In vitro therapy investigation for breast cancer by B13-chloroquine application. BioDiCon. 2024;17(2):105-111. doi:10.46309/biodicon.2024.1353221
Chicago
Çömlekçi, Emre, Canan Vejselova Sezer, Hatice Mehtap Kutlu, Ömer Koray Yaylacı, and Gokhan Kus. 2024. “In Vitro Therapy Investigation for Breast Cancer by B13-Chloroquine Application”. Biological Diversity and Conservation 17 (2): 105-11. https://doi.org/10.46309/biodicon.2024.1353221.
EndNote
Çömlekçi E, Vejselova Sezer C, Kutlu HM, Yaylacı ÖK, Kus G (August 1, 2024) In vitro therapy investigation for breast cancer by B13-chloroquine application. Biological Diversity and Conservation 17 2 105–111.
IEEE
[1]E. Çömlekçi, C. Vejselova Sezer, H. M. Kutlu, Ö. K. Yaylacı, and G. Kus, “In vitro therapy investigation for breast cancer by B13-chloroquine application”, BioDiCon, vol. 17, no. 2, pp. 105–111, Aug. 2024, doi: 10.46309/biodicon.2024.1353221.
ISNAD
Çömlekçi, Emre - Vejselova Sezer, Canan - Kutlu, Hatice Mehtap - Yaylacı, Ömer Koray - Kus, Gokhan. “In Vitro Therapy Investigation for Breast Cancer by B13-Chloroquine Application”. Biological Diversity and Conservation 17/2 (August 1, 2024): 105-111. https://doi.org/10.46309/biodicon.2024.1353221.
JAMA
1.Çömlekçi E, Vejselova Sezer C, Kutlu HM, Yaylacı ÖK, Kus G. In vitro therapy investigation for breast cancer by B13-chloroquine application. BioDiCon. 2024;17:105–111.
MLA
Çömlekçi, Emre, et al. “In Vitro Therapy Investigation for Breast Cancer by B13-Chloroquine Application”. Biological Diversity and Conservation, vol. 17, no. 2, Aug. 2024, pp. 105-11, doi:10.46309/biodicon.2024.1353221.
Vancouver
1.Emre Çömlekçi, Canan Vejselova Sezer, Hatice Mehtap Kutlu, Ömer Koray Yaylacı, Gokhan Kus. In vitro therapy investigation for breast cancer by B13-chloroquine application. BioDiCon. 2024 Aug. 1;17(2):105-11. doi:10.46309/biodicon.2024.1353221

❖  Indexes
Additional Web of Science Indexes: Zoological Record, TR Dizin, Medical Reads (RRS), CrossRef;10.46309/biodicon.

❖  Libraries
Aberystwyth University; All libraries; Bath University; Birmingham University; Cardiff University; City University London; CONSER (Not UK Holdings); Edinburgh University; Essex University;Eskisehir Technical University Library, Exeter University; EZB Electronic Journals Library; Feng Chia University Library; GAZİ Gazi University Library; Glasgow University; HEC-National Digital Library; Hull University; Imperial College London; Kaohsiung Medical University Library; ANKOS; Anadolu University Library; Lancaster University; Libros PDF; Liverpool University; London Metropolitan University; London School of Economics and Political Science; Manchester University; National Cheng Kung University Library; National ILAN University Library; Nottingham University; Open University; Oxford University; Queen Mary, University of London; Robert Gordon University; Royal Botanic Gardens, Kew; Sheffield Hallam University; Sheffield University; Shih Hsin University Library; Smithsonian Institution Libraries; Southampton University; Stirling University; Strathclyde University; Sussex University; The National Agricultural Library (NAL); The Ohio Library and Information NetWork; Trinity College Dublin; University of Washington Libraries; Vaughan Memorial Library; York University. 

❖ Articles published in the journal “Biological Diversity and Conservation” are freely accessible. No article processing charge (APC) is charged.

❖ Additional Web of Science Indexes: Zoological Record
❖ This journal is a member of CrossRef;10.46309/biodicon. 
❖ For published articles and full details about the journal, please visit http://www.biodicon.com; https://dergipark.org.tr/tr/yayin/biodicon. 


❖  Correspondence Address:: Prof. Ersin YÜCEL, Sazova Mahallesi, Ziraat Caddesi, No.277 F Blok, 26005 Tepebaşı-Eskişehir/Türkiye 
E-mail: biodicon@gmail.com; 
❖ Web Address: http://www.biodicon.com;  https://dergipark.org.tr/tr/pub/biodicon 
❖ Biological Diversity and Conservation 
❖ ISSN 1308-5301 Print; ISSN 1308-8084 Online 
Publication Start Date 2008 
© Copyright by Biological Diversity and Conservation/Biyolojik Çeşitlilik ve Koruma;  Available online at www.biodicon.com. All rights reserved.
. ❖ Publisher: ERSİN YÜCEL (https://www.ersinyucel.com.tr) 
❖ This Journal is published four times a year. It is printed in Eskişehir, Türkiye. 
❖ The authors are solely responsible for the articles published in this Journal . 
Editör-in Chief  : Prof.Dr. Ersin YÜCEL, https://orcid.org/0000-0001-8274-7578